Viridian Therapeutics Inc... (VRDN)
13.10
0.54 (4.30%)
At close: Apr 02, 2025, 3:59 PM
13.46
2.71%
After-hours: Apr 02, 2025, 07:55 PM EDT
4.30% (1D)
| Bid | 12.53 |
| Market Cap | 1.07B |
| Revenue (ttm) | n/a |
| Net Income (ttm) | n/a |
| EPS (ttm) | -3.07 |
| PE Ratio (ttm) | -4.27 |
| Forward PE | -4.55 |
| Analyst | Buy |
| Ask | 13.51 |
| Volume | 766,003 |
| Avg. Volume (20D) | 991,691 |
| Open | 12.41 |
| Previous Close | 12.56 |
| Day's Range | 12.41 - 13.28 |
| 52-Week Range | 11.40 - 27.20 |
| Beta | 1.09 |
About VRDN
Viridian Therapeutics, Inc., a biotechnology company, develops treatments for patients suffering from serious diseases. It develops VRDN-001, a humanized monoclonal anti-IGF-1R antibody that is in Phase 1/2 clinical trial for the treatment of thyroid eye disease (TED); VRDN-002, an IGF-1R antibody, which is in Phase 1 clinical trial; and VRDN-003, a therapeutic antibody targeting IGF-1R for the treatment of TED. The company was formerly known as ...
Industry Biotechnology
Sector Healthcare
IPO Date Jun 18, 2014
Employees 143
Stock Exchange NASDAQ
Ticker Symbol VRDN
Analyst Forecast
According to 12 analyst ratings, the average rating for VRDN stock is "Buy." The 12-month stock price forecast is $34, which is an increase of 159.54% from the latest price.
Stock ForecastsNext Earnings Release
Viridian Therapeutics Inc. is scheduled to release its earnings on May 7, 2025,
before market opens.
Analysts project revenue of ... Unlock content with Pro Subscription
Analysts project revenue of ... Unlock content with Pro Subscription
3 months ago
+20.67%
Viridian Therapeutics shares are trading higher af...
Unlock content with
Pro Subscription
6 months ago
+7.76%
Viridian Therapeutics shares are trading higher after BTIG raised its price target on the stock from $56 to $61.
